Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. (2022)
Attributed to:
Phase 1 evaluation of CRISPR-CAR gene edited T cells in relapsed refractory B cell acute lymphoblastic leukaemia
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.abq3010
PubMed Identifier: 36288281
Publication URI: http://europepmc.org/abstract/MED/36288281
Type: Journal Article/Review
Volume: 14
Parent Publication: Science translational medicine
Issue: 668
ISSN: 1946-6234